Vaccines and Emerging/Re-Emerging Virus Diseases
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 4474
Special Issue Editor
Interests: poxvirus; flavivirus; vruses in the family filoviridae; arenavirus; hepatitis e virus; coronavirus; orthomyxovirus; bunyavirus
Special Issue Information
Dear Colleagues,
Over the past decade, an alarming number of infectious viruses have emerged or re-emerged, presenting great threats to global health and to the economy worldwide. Ebola and Marburg hemorrhagic fevers, Lassa fever, Dengue fever, Yellow fever, West Nile fever, Zika, Poxvirus; Flavivirus; Arenavirus; Hepatitis E Virus; Orthomyxovirus; Bunyavirus and Chikungunya vector-borne diseases, Swine flu, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), avian influenza viruses, and the recent coronavirus disease 2019 (COVID-19) are examples of zoonoses that have spread throughout the globe with such a significant impact on public health that the scientific community has been called for a rapid intervention in preventing and treating emerging infections. Vaccination is probably the most effective tool in helping the immune system to activate protective responses against pathogens, reducing morbidity and mortality, as proven by historical records. Under health emergency conditions, new and alternative approaches in vaccine design and development are imperative for a rapid and massive vaccination coverage, to manage a disease outbreak and curtail epidemic spread. This issue offers an update on current vaccination strategies for some emerging/re-emerging viruses and discusses challenges and hurdles to overcome for developing efficacious vaccines against viral diseases.
Dr. Daniele Lapa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
